NASDAQ: DTIL PRECISION BIOSCIENCES INC 8-K

Precision BioSciences reports positive Phase 1 hepatitis B trial data showing viral DNA elimination

Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade DTIL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 27, 2026 9:45 PM